Artelo Biosciences (ARTL) Stock Analysis

What Artelo Biosciences does

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Key metrics

ETFs linked to ARTL

Broad-market and Healthcare sector ETFs an investor holding Artelo Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ARTL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Artelo Biosciences?

Artelo Biosciences trades under the ticker ARTL on NASDAQ.

Which exchange is ARTL listed on?

ARTL is listed on NASDAQ.

What sector does Artelo Biosciences operate in?

Artelo Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ARTL in a portfolio?

PortView shows ARTL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.